Current role
Biotechnology · Healthcare
CEO, Board Member
2026-04-20–present
Pedro Beltran, Ph.D.
Equibles does not estimate personal net worth.
Get an email with a short summary when BridgeBio Oncology Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get BBOT alertsAbout Pedro Beltran, Ph.D.
Pedro Beltran, Ph.D. is recorded as CEO and Board Member at BridgeBio Oncology Therapeutics, Inc. (BBOT) since April 20, 2026. BridgeBio Oncology Therapeutics, Inc. reported in an 8-K filed April 23, 2026 that Pedro Beltran, Ph.D. was appointed Class III director, effective April 20, 2026. BridgeBio Oncology Therapeutics, Inc. reported in an 8-K filed April 23, 2026 that Pedro Beltran, Ph.D. was appointed President and Chief Executive Officer, effective April 20, 2026. BridgeBio Oncology Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at BridgeBio Oncology Therapeutics, Inc. includes Eli Wallace (CEO and Board Member), Pedro J. Beltran, Ph.D. (CEO and Board Member), Neil Kumar, Ph.D. (Chairman) and 7 others.
“the Board appointed Dr. Beltran as a Class III director to fill the vacancy created by Dr. Wallace’s resignation, effective immediately.”
“On April 20, 2026, the Board of Directors (the “Board”) of BridgeBio Oncology Therapeutics, Inc. (the “Company”) approved the appointment of Pedro Beltran, Ph.D., as the Company’s President and Chief Executive Officer (“CEO”) (and as the Company’s principal executive officer), effective immediately.”
Affiliation history
-
Current
2026-04-20–present
-
Current
2026-04-20–present
Company network
Leadership on record at BridgeBio Oncology Therapeutics, Inc.
- Eli Wallace CEO, Board Member
- Pedro J. Beltran, Ph.D. CEO, Board Member
- Neil Kumar, Ph.D. Chairman
- Idan Elmelech CFO, COO
- Uneek Mehra CFO
- Marc Cobo Chief Accounting Officer
- Albert A. Holman, III Board Member
- Bihua Chen Board Member
- Frank McCormick Board Member
- Frank P. McCormick Board Member